Journal
ADVANCED FUNCTIONAL MATERIALS
Volume 30, Issue 12, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.201908961
Keywords
checkpoint blockade immunotherapy; HPMA polymer; immunogenic cell death; immunosuppressive tumor; PD-L1 crosslinking
Categories
Funding
- NIH [R42 CA156933]
- TheraTarget
- [P30 CS042014]
Ask authors/readers for more resources
Checkpoint blockade immunotherapies harness the host's own immune system to fight cancer, but only work against tumors infiltrated by swarms of preexisting T cells. Unfortunately, most cancers to date are immune-deserted. Here, a polymer-assisted combination of immunogenic chemotherapy and PD-L1 degradation is reported for efficacious treatment in originally nonimmunogenic cancer. Priming tumors with backbone-degradable polymer-epirubicin conjugates elicits immunogenic cell death and fosters tumor-specific CD8+ T cell response. Sequential treatment with a multivalent polymer-peptide antagonist to PD-L1 overcomes adaptive PD-L1 enrichment following chemotherapy, biases the recycling of PD-L1 to lysosome degradation via surface receptor crosslinking, and produces prolonged elimination of PD-L1 rather than the transient blocking afforded by standard anti-PD-L1 antibodies. Together, these findings establish the polymer-facilitated tumor targeting of immunogenic drugs and surface crosslinking of PD-L1 as a potential new therapeutic strategy to propagate long-term antitumor immunity, which might broaden the application of immunotherapy to immunosuppressive cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available